Detalhe da pesquisa
1.
Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases.
Gastroenterology
; 166(3): 396-408.e2, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37949249
2.
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression.
Clin Gastroenterol Hepatol
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38428709
3.
Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Clin Gastroenterol Hepatol
; 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185396
4.
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
Am J Gastroenterol
; 2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235763
5.
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 21(4): 1050-1060.e9, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029969
6.
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
Clin Gastroenterol Hepatol
; 21(13): 3387-3396.e1, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37391059
7.
Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol
; 21(10): 2483-2495.e1, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36731590
8.
Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study.
Clin Gastroenterol Hepatol
; 21(10): 2649-2659.e16, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528284
9.
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
Am J Gastroenterol
; 118(1): 121-128, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066459
10.
Patients With Crohn's Disease and Permanent Ileostomy Are Universally Excluded From Clinical Trials: A Systematic Review.
Am J Gastroenterol
; 118(7): 1285-1288, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36757156
11.
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study.
Am J Gastroenterol
; 118(5): 861-871, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580497
12.
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Am J Gastroenterol
; 118(2): 317-328, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36191274
13.
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.
J Clin Gastroenterol
; 57(9): 913-919, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36227009
14.
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
Scand J Gastroenterol
; 58(1): 7-14, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35909369
15.
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.
Dig Dis Sci
; 68(6): 2658-2666, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36645636
16.
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.
Dig Dis Sci
; 68(6): 2635-2646, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37119375
17.
Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis.
Dig Dis Sci
; 68(9): 3702-3713, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37378711
18.
Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study.
Saudi Pharm J
; 31(9): 101736, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37638216
19.
Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
Gut
; 71(6): 1078-1087, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33766910
20.
Clinical Decision Support Tool for Infliximab in Crohn's Disease.
Clin Gastroenterol Hepatol
; 20(5): e1192-e1195, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216825